Download PDF
Semin Reprod Med 2011; 29(3): 211-224
DOI: 10.1055/s-0031-1275522
© Thieme Medical Publishers

In Utero Origins of Adult Insulin Resistance and Vascular Dysfunction

Jennifer A. Thompson1 , Timothy R.H. Regnault1
  • 1Departments of Obstetrics and Gynaecology and Physiology and Pharmacology, Children's Health Research Institute and Lawson Research Institute, University of Western Ontario, London, Ontario, Canada
Further Information

Publication History

Publication Date:
27 June 2011 (online)

    Permissions and Reprints

ABSTRACT

The metabolic syndrome (or syndrome X) is a constellation of risk factors including insulin resistance, hypertension, dyslipidemia, and central obesity that predispose to the development of cardiovascular disease and type 2 diabetes in adult life. Insulin resistance is believed to be a critical pathophysiological event early in the disease process, impacting both skeletal muscle metabolic function and vascular responses. Adverse changes in insulin sensitivity have been found to originate in utero; for instance, prenatal events such as placental insufficiency/oxidative stress leading to altered fetal growth trajectories are associated with increased rates of metabolic syndrome in adult life. Such intrauterine insults result in reduced skeletal muscle mass in conjunction with altered insulin signaling, decreased oxidative fibers, and impaired mitochondrial function. These developmental disturbances set the stage for development of muscle triglyceride accumulation and depressed insulin sensitivity in childhood. Abnormalities of vascular structure and function arising from deprived intrauterine conditions that are exacerbated by insulin resistance account for the progression of hypertension from childhood to adulthood. Arterial changes initiated in utero include reduced endothelial nitric oxide (NO) bioavailability, vascular smooth muscle cell proliferation and inflammation, events leading to endothelial dysfunction, and atherosclerosis that are present in those destined for metabolic syndrome. In addition, the hypertensive phenotype that is a hallmark of metabolic syndrome may also be traced to blunted kidney development and renin-angiotensin system activation in growth-restricted offspring. The summative impact of these intrauterine programmed changes in terms of influencing adult health and disease encompasses dietary and lifestyle factors introduced postnatally. Establishing novel therapeutic interventions aimed at preventing and/or reducing in utero–induced insulin resistance and vascular dysfunction warrants investigation because the numbers of low birthweight babies continue to increase.

KEYWORDS

Fetus - programming - adult - muscle - insulin resistance - vessels - vascular dysfunction - endothelial dysfunction

REFERENCES

  • 1 Osmond C, Barker D J. Fetal, infant, and childhood growth are predictors of coronary heart disease, diabetes, and hypertension in adult men and women.  Environ Health Perspect. 2000;  108 (Suppl 3) 545-553
    PubMedGoogle Scholar
  • 2 Ross M G, Beall M H. Adult sequelae of intrauterine growth restriction.  Semin Perinatol. 2008;  32 (3) 213-218
    CrossrefPubMedGoogle Scholar
  • 3 Eriksson J G, Forsén T, Tuomilehto J, Winter P D, Osmond C, Barker D J. Catch-up growth in childhood and death from coronary heart disease: longitudinal study.  BMJ. 1999;  318 (7181) 427-431
    CrossrefPubMedGoogle Scholar
  • 4 Arends N J, Boonstra V H, Duivenvoorden H J, Hofman P L, Cutfield W S, Hokken-Koelega A C. Reduced insulin sensitivity and the presence of cardiovascular risk factors in short prepubertal children born small for gestational age (SGA).  Clin Endocrinol (Oxf). 2005;  62 (1) 44-50
    CrossrefPubMedGoogle Scholar
  • 5 Barker D J, Osmond C, Forsén T J, Kajantie E, Eriksson J G. Trajectories of growth among children who have coronary events as adults.  N Engl J Med. 2005;  353 (17) 1802-1809
    CrossrefPubMedGoogle Scholar
  • 6 Morton J S, Rueda-Clausen C F, Davidge S T. Mechanisms of endothelium-dependent vasodilation in male and female, young and aged offspring born growth restricted.  Am J Physiol Regul Integr Comp Physiol. 2010;  298 (4) R930-R938
    CrossrefPubMedGoogle Scholar
  • 7 Barker D J. The developmental origins of insulin resistance.  Horm Res. 2005;  64 (Suppl 3) 2-7
    CrossrefPubMedGoogle Scholar
  • 8 Stary H C. Evolution and progression of atherosclerotic lesions in coronary arteries of children and young adults.  Arteriosclerosis. 1989;  9 (1, Suppl) I19-I32
    PubMedGoogle Scholar
  • 9 Singhal A. Endothelial dysfunction: role in obesity-related disorders and the early origins of CVD.  Proc Nutr Soc. 2005;  64 (1) 15-22
    CrossrefPubMedGoogle Scholar
  • 10 Ness R B, Sibai B M. Shared and disparate components of the pathophysiologies of fetal growth restriction and preeclampsia.  Am J Obstet Gynecol. 2006;  195 (1) 40-49
    PubMedGoogle Scholar
  • 11 Regnault T R, de Vrijer B, Galan H L, Wilkening R B, Battaglia F C, Meschia G. Development and mechanisms of fetal hypoxia in severe fetal growth restriction.  Placenta. 2007;  28 (7) 714-723
    CrossrefPubMedGoogle Scholar
  • 12 Mayhew T M, Manwani R, Ohadike C, Wijesekara J, Baker P N. The placenta in pre-eclampsia and intrauterine growth restriction: studies on exchange surface areas, diffusion distances and villous membrane diffusive conductances.  Placenta. 2006;  28 (3) 233-238
    PubMedGoogle Scholar
  • 13 Resnik R. Intrauterine growth restriction.  Obstet Gynecol. 2002;  99 (3) 490-496
    CrossrefPubMedGoogle Scholar
  • 14 Marconi A M, Paolini C L, Stramare L et al.. Steady state maternal-fetal leucine enrichments in normal and intrauterine growth-restricted pregnancies.  Pediatr Res. 1999;  46 (1) 114-119
    CrossrefPubMedGoogle Scholar
  • 15 Paolini C L, Marconi A M, Ronzoni S et al.. Placental transport of leucine, phenylalanine, glycine, and proline in intrauterine growth-restricted pregnancies.  J Clin Endocrinol Metab. 2001;  86 (11) 5427-5432
    CrossrefPubMedGoogle Scholar
  • 16 Thureen P J, Trembler K A, Meschia G, Makowski E L, Wilkening R B. Placental glucose transport in heat-induced fetal growth retardation.  Am J Physiol. 1992;  263 (3 Pt 2) R578-R585
    PubMedGoogle Scholar
  • 17 Alvino G, Cozzi V, Radaelli T, Ortega H, Herrera E, Cetin I. Maternal and fetal fatty acid profile in normal and intrauterine growth restriction pregnancies with and without preeclampsia.  Pediatr Res. 2008;  64 (6) 615-620
    CrossrefPubMedGoogle Scholar
  • 18 Rodie V A, Caslake M J, Stewart F et al.. Fetal cord plasma lipoprotein status in uncomplicated human pregnancies and in pregnancies complicated by pre-eclampsia and intrauterine growth restriction.  Atherosclerosis. 2004;  176 (1) 181-187
    Google Scholar
  • 19 Lackman F, Capewell V, Gagnon R, Richardson B. Fetal umbilical cord oxygen values and birth to placental weight ratio in relation to size at birth.  Am J Obstet Gynecol. 2001;  185 (3) 674-682
    CrossrefPubMedGoogle Scholar
  • 20 Cheema R, Dubiel M, Gudmundsson S. Signs of fetal brain sparing are not related to umbilical cord blood gases at birth.  Early Hum Dev. 2009;  85 (7) 467-470
    CrossrefPubMedGoogle Scholar
  • 21 Arbeille P. Fetal arterial Doppler-IUGR and hypoxia.  Eur J Obstet Gynecol Reprod Biol. 1997;  75 (1) 51-53
    CrossrefPubMedGoogle Scholar
  • 22 Baschat A A. Fetal responses to placental insufficiency: an update.  BJOG. 2004;  111 (10) 1031-1041
    CrossrefPubMedGoogle Scholar
  • 23 Rurak D W, Richardson B S, Patrick J E, Carmichael L, Homan J. Blood flow and oxygen delivery to fetal organs and tissues during sustained hypoxemia.  Am J Physiol. 1990;  258 (5 Pt 2) R1116-R1122
    PubMedGoogle Scholar
  • 24 Verkauskiene R, Beltrand J, Claris O et al.. Impact of fetal growth restriction on body composition and hormonal status at birth in infants of small and appropriate weight for gestational age.  Eur J Endocrinol. 2007;  157 (5) 605-612
    CrossrefPubMedGoogle Scholar
  • 25 Widdowson E M, Crabb D E, Milner R D. Cellular development of some human organs before birth.  Arch Dis Child. 1972;  47 (254) 652-655
    CrossrefPubMedGoogle Scholar
  • 26 Mi J, Cheng H, Zhao X Y, Hou D Q, Chen F F, Zhang K L. Developmental origin of metabolic syndrome: interaction of thinness at birth and overweight during adult life in Chinese population.  Obes Rev. 2008;  9 (Suppl 1) 91-94
    CrossrefPubMedGoogle Scholar
  • 27 Marconi A M, Ronzoni S, Vailati S, Bozzetti P, Morabito A, Battaglia F C. Neonatal morbidity and mortality in intrauterine growth restricted (IUGR) pregnancies is predicated upon prenatal diagnosis of clinical severity.  Reprod Sci. 2009;  16 (4) 373-379
    PubMedGoogle Scholar
  • 28 Ozanne S E, Constância M. Mechanisms of disease: the developmental origins of disease and the role of the epigenotype.  Nat Clin Pract Endocrinol Metab. 2007;  3 (7) 539-546
    CrossrefPubMedGoogle Scholar
  • 29 Gluckman P D, Hanson M A, Cooper C, Thornburg K L. Effect of in utero and early-life conditions on adult health and disease.  N Engl J Med. 2008;  359 (1) 61-73
    CrossrefPubMedGoogle Scholar
  • 30 Rogers M S, Murray H G, Wang C C et al.. Oxidative stress in the fetal lamb brain following intermittent umbilical cord occlusion: a path analysis.  BJOG. 2001;  108 (12) 1283-1290
    PubMedGoogle Scholar
  • 31 Baker J E. Oxidative stress and adaptation of the infant heart to hypoxia and ischemia.  Antioxid Redox Signal. 2004;  6 (2) 423-429
    CrossrefPubMedGoogle Scholar
  • 32 Grattagliano I, Palmieri V O, Portincasa P, Moschetta A, Palasciano G. Oxidative stress-induced risk factors associated with the metabolic syndrome: a unifying hypothesis.  J Nutr Biochem. 2008;  19 (8) 491-504
    CrossrefPubMedGoogle Scholar
  • 33 Tintu A N, Noble F A, Rouwet E V. Hypoxia disturbs fetal hemodynamics and growth.  Endothelium. 2007;  14 (6) 353-360
    CrossrefPubMedGoogle Scholar
  • 34 Fernandez-Twinn D S, Ozanne S E. Mechanisms by which poor early growth programs type-2 diabetes, obesity and the metabolic syndrome.  Physiol Behav. 2006;  88 (3) 234-243
    CrossrefPubMedGoogle Scholar
  • 35 Luo Z C, Fraser W D, Julien P et al.. Tracing the origins of “fetal origins” of adult diseases: programming by oxidative stress?.  Med Hypotheses. 2006;  66 (1) 38-44
    CrossrefPubMedGoogle Scholar
  • 36 Jensen C B, Martin-Gronert M S, Storgaard H, Madsbad S, Vaag A, Ozanne S E. Altered PI3-kinase/Akt signalling in skeletal muscle of young men with low birth weight.  PLoS ONE. 2008;  3 (11) e3738
    CrossrefPubMedGoogle Scholar
  • 37 Singhal A, Fewtrell M, Cole T J, Lucas A. Low nutrient intake and early growth for later insulin resistance in adolescents born preterm.  Lancet. 2003;  361 (9363) 1089-1097
    CrossrefPubMedGoogle Scholar
  • 38 Phillips D I. Insulin resistance as a programmed response to fetal undernutrition.  Diabetologia. 1996;  39 (9) 1119-1122
    CrossrefPubMedGoogle Scholar
  • 39 Jaquet D, Deghmoun S, Chevenne D, Collin D, Czernichow P, Lévy-Marchal C. Dynamic change in adiposity from fetal to postnatal life is involved in the metabolic syndrome associated with reduced fetal growth.  Diabetologia. 2005;  48 (5) 849-855
    CrossrefPubMedGoogle Scholar
  • 40 Eriksson J G, Forsén T, Tuomilehto J, Jaddoe V W, Osmond C, Barker D J. Effects of size at birth and childhood growth on the insulin resistance syndrome in elderly individuals.  Diabetologia. 2002;  45 (3) 342-348
    CrossrefPubMedGoogle Scholar
  • 41 Jaquet D, Gaboriau A, Czernichow P, Levy-Marchal C. Insulin resistance early in adulthood in subjects born with intrauterine growth retardation.  J Clin Endocrinol Metab. 2000;  85 (4) 1401-1406
    CrossrefPubMedGoogle Scholar
  • 42 Hofman P L, Cutfield W S, Robinson E M et al.. Insulin resistance in short children with intrauterine growth retardation.  J Clin Endocrinol Metab. 1997;  82 (2) 402-406
    CrossrefPubMedGoogle Scholar
  • 43 Karlberg J P, Albertsson-Wikland K, Kwan E Y, Lam B C, Low L C. The timing of early postnatal catch-up growth in normal, full-term infants born short for gestational age.  Horm Res. 1997;  48 (Suppl 1) 17-24
    CrossrefPubMedGoogle Scholar
  • 44 Louey S, Cock M L, Harding R. Long term consequences of low birthweight on postnatal growth, adiposity and brain weight at maturity in sheep.  J Reprod Dev. 2005;  51 (1) 59-68
    CrossrefPubMedGoogle Scholar
  • 45 Cosmi E, Visentin S, Fanelli T, Mautone A J, Zanardo V. Aortic intima media thickness in fetuses and children with intrauterine growth restriction.  Obstet Gynecol. 2009;  114 (5) 1109-1114
    CrossrefPubMedGoogle Scholar
  • 46 Contreras C, Sánchez A, Martínez P et al.. Insulin resistance in penile arteries from a rat model of metabolic syndrome.  Br J Pharmacol. 2010;  161 (2) 350-364
    CrossrefPubMedGoogle Scholar
  • 47 Cunningham J T, Rodgers J T, Arlow D H, Vazquez F, Mootha V K, Puigserver P. mTOR controls mitochondrial oxidative function through a YY1-PGC-1alpha transcriptional complex.  Nature. 2007;  450 (7170) 736-740
    CrossrefPubMedGoogle Scholar
  • 48 Dressel U, Allen T L, Pippal J B, Rohde P R, Lau P, Muscat G E. The peroxisome proliferator-activated receptor beta/delta agonist, GW501516, regulates the expression of genes involved in lipid catabolism and energy uncoupling in skeletal muscle cells.  Mol Endocrinol. 2003;  17 (12) 2477-2493
    CrossrefPubMedGoogle Scholar
  • 49 Schuler M, Ali F, Chambon C et al.. PGC1alpha expression is controlled in skeletal muscles by PPARbeta, whose ablation results in fiber-type switching, obesity, and type 2 diabetes.  Cell Metab. 2006;  4 (5) 407-414
    CrossrefPubMedGoogle Scholar
  • 50 Krämer D K, Ahlsén M, Norrbom J et al.. Human skeletal muscle fibre type variations correlate with PPAR alpha, PPAR delta and PGC-1 alpha mRNA.  Acta Physiol (Oxf). 2006;  188 (3–4) 207-216
    CrossrefPubMedGoogle Scholar
  • 51 Loviscach M, Rehman N, Carter L et al.. Distribution of peroxisome proliferator-activated receptors (PPARs) in human skeletal muscle and adipose tissue: relation to insulin action.  Diabetologia. 2000;  43 (3) 304-311
    CrossrefPubMedGoogle Scholar
  • 52 Handel S E, Stickland N C. The effects of low birthweight on the ultrastructural development of two myofibre types in the pig.  J Anat. 1987;  150 129-143
    PubMedGoogle Scholar
  • 53 Picard B, Lefaucheur L, Berri C, Duclos M J. Muscle fibre ontogenesis in farm animal species.  Reprod Nutr Dev. 2002;  42 (5) 415-431
    CrossrefPubMedGoogle Scholar
  • 54 He J, Watkins S, Kelley D E. Skeletal muscle lipid content and oxidative enzyme activity in relation to muscle fiber type in type 2 diabetes and obesity.  Diabetes. 2001;  50 (4) 817-823
    CrossrefPubMedGoogle Scholar
  • 55 Fahey A J, Brameld J M, Parr T, Buttery P J. Ontogeny of factors associated with proliferation and differentiation of muscle in the ovine fetus.  J Anim Sci. 2005;  83 (10) 2330-2338
    PubMedGoogle Scholar
  • 56 McCoard S A, McNabb W C, Peterson S W, McCutcheon S N, Harris P M. Muscle growth, cell number, type and morphometry in single and twin fetal lambs during mid to late gestation.  Reprod Fertil Dev. 2000;  12 (5–6) 319-327
    CrossrefPubMedGoogle Scholar
  • 57 Tilley R E, McNeil C J, Ashworth C J, Page K R, Mcardle H J. Altered muscle development and expression of the insulin-like growth factor system in growth retarded fetal pigs.  Domest Anim Endocrinol. 2007;  32 (3) 167-177
    CrossrefPubMedGoogle Scholar
  • 58 Rees W D, Hay S M, Cruickshank M et al.. Maternal protein intake in the pregnant rat programs the insulin axis and body composition in the offspring.  Metabolism. 2006;  55 (5) 642-649
    CrossrefPubMedGoogle Scholar
  • 59 Nyholm B, Qu Z, Kaal A et al.. Evidence of an increased number of type IIb muscle fibers in insulin-resistant first-degree relatives of patients with NIDDM.  Diabetes. 1997;  46 (11) 1822-1828
    CrossrefPubMedGoogle Scholar
  • 60 Lagouge M, Argmann C, Gerhart-Hines Z et al.. Resveratrol improves mitochondrial function and protects against metabolic disease by activating SIRT1 and PGC-1alpha.  Cell. 2006;  127 (6) 1109-1122
    CrossrefPubMedGoogle Scholar
  • 61 Malenfant P, Joanisse D R, Thériault R, Goodpaster B H, Kelley D E, Simoneau J A. Fat content in individual muscle fibers of lean and obese subjects.  Int J Obes Relat Metab Disord. 2001;  25 (9) 1316-1321
    CrossrefPubMedGoogle Scholar
  • 62 Zhu M J, Ford S P, Means W J, Hess B W, Nathanielsz P W, Du M. Maternal nutrient restriction affects properties of skeletal muscle in offspring.  J Physiol. 2006;  575 (Pt 1) 241-250
    CrossrefPubMedGoogle Scholar
  • 63 DeFronzo R A. Pathogenesis of type 2 (non-insulin dependent) diabetes mellitus: a balanced overview.  Diabetologia. 1992;  35 (4) 389-397
    CrossrefPubMedGoogle Scholar
  • 64 Taniguchi C M, Emanuelli B, Kahn C R. Critical nodes in signalling pathways: insights into insulin action.  Nat Rev Mol Cell Biol. 2006;  7 (2) 85-96
    CrossrefPubMedGoogle Scholar
  • 65 Fingar D C, Richardson C J, Tee A R, Cheatham L, Tsou C, Blenis J. mTOR controls cell cycle progression through its cell growth effectors S6K1 and 4E-BP1/eukaryotic translation initiation factor 4E.  Mol Cell Biol. 2004;  24 (1) 200-216
    CrossrefPubMedGoogle Scholar
  • 66 Thorn S R, Regnault T R, Brown L D et al.. Intrauterine growth restriction increases fetal hepatic gluconeogenic capacity and reduces messenger ribonucleic acid translation initiation and nutrient sensing in fetal liver and skeletal muscle.  Endocrinology. 2009;  150 (7) 3021-3030
    CrossrefPubMedGoogle Scholar
  • 67 Muhlhausler B S, Duffield J A, Ozanne S E et al.. The transition from fetal growth restriction to accelerated postnatal growth: a potential role for insulin signalling in skeletal muscle.  J Physiol. 2009;  587 (Pt 17) 4199-4211
    CrossrefPubMedGoogle Scholar
  • 68 Fahey A J, Brameld J M, Parr T, Buttery P J. The effect of maternal undernutrition before muscle differentiation on the muscle fiber development of the newborn lamb.  J Anim Sci. 2005;  83 (11) 2564-2571
    PubMedGoogle Scholar
  • 69 Zhu M J, Ford S P, Nathanielsz P W, Du M. Effect of maternal nutrient restriction in sheep on the development of fetal skeletal muscle.  Biol Reprod. 2004;  71 (6) 1968-1973
    CrossrefPubMedGoogle Scholar
  • 70 Basu A, Lenka N, Mullick J, Avadhani N G. Regulation of murine cytochrome oxidase Vb gene expression in different tissues and during myogenesis. Role of a YY-1 factor-binding negative enhancer.  J Biol Chem. 1997;  272 (9) 5899-5908
    CrossrefPubMedGoogle Scholar
  • 71 Schieke S M, Phillips D, McCoy Jr J P et al.. The mammalian target of rapamycin (mTOR) pathway regulates mitochondrial oxygen consumption and oxidative capacity.  J Biol Chem. 2006;  281 (37) 27643-27652
    CrossrefPubMedGoogle Scholar
  • 72 Selak M A, Storey B T, Peterside I, Simmons R A. Impaired oxidative phosphorylation in skeletal muscle of intrauterine growth-retarded rats.  Am J Physiol Endocrinol Metab. 2003;  285 (1) E130-E137
    PubMedGoogle Scholar
  • 73 Thamer C, Stumvoll M, Niess A et al.. Reduced skeletal muscle oxygen uptake and reduced beta-cell function: two early abnormalities in normal glucose-tolerant offspring of patients with type 2 diabetes.  Diabetes Care. 2003;  26 (7) 2126-2132
    CrossrefPubMedGoogle Scholar
  • 74 Dressel U, Allen T L, Pippal J B, Rohde P R, Lau P, Muscat G E. The peroxisome proliferator-activated receptor beta/delta agonist, GW501516, regulates the expression of genes involved in lipid catabolism and energy uncoupling in skeletal muscle cells.  Mol Endocrinol. 2003;  17 (12) 2477-2493
    CrossrefPubMedGoogle Scholar
  • 75 Lin J, Wu H, Tarr P T et al.. Transcriptional co-activator PGC-1 alpha drives the formation of slow-twitch muscle fibres.  Nature. 2002;  418 (6899) 797-801
    CrossrefPubMedGoogle Scholar
  • 76 Benton C R, Nickerson J G, Lally J et al.. Modest PGC-1alpha overexpression in muscle in vivo is sufficient to increase insulin sensitivity and palmitate oxidation in subsarcolemmal, not intermyofibrillar, mitochondria.  J Biol Chem. 2008;  283 (7) 4228-4240
    PubMedGoogle Scholar
  • 77 Mensink M, Hesselink M K, Russell A P, Schaart G, Sels J P, Schrauwen P. Improved skeletal muscle oxidative enzyme activity and restoration of PGC-1 alpha and PPAR beta/delta gene expression upon rosiglitazone treatment in obese patients with type 2 diabetes mellitus.  Int J Obes (Lond). 2007;  31 (8) 1302-1310
    CrossrefPubMedGoogle Scholar
  • 78 Patti M E, Butte A J, Crunkhorn S et al.. Coordinated reduction of genes of oxidative metabolism in humans with insulin resistance and diabetes: Potential role of PGC1 and NRF1.  Proc Natl Acad Sci U S A. 2003;  100 (14) 8466-8471
    CrossrefPubMedGoogle Scholar
  • 79 Lane R H, MacLennan N K, Hsu J L, Janke S M, Pham T D. Increased hepatic peroxisome proliferator-activated receptor-gamma coactivator-1 gene expression in a rat model of intrauterine growth retardation and subsequent insulin resistance.  Endocrinology. 2002;  143 (7) 2486-2490
    CrossrefPubMedGoogle Scholar
  • 80 Jucker B M, Yang D, Casey W M et al.. Selective PPARdelta agonist treatment increases skeletal muscle lipid metabolism without altering mitochondrial energy coupling: an in vivo magnetic resonance spectroscopy study.  Am J Physiol Endocrinol Metab. 2007;  293 (5) E1256-E1264
    CrossrefPubMedGoogle Scholar
  • 81 Koopman R, Schaart G, Hesselink M K. Optimisation of oil red O staining permits combination with immunofluorescence and automated quantification of lipids.  Histochem Cell Biol. 2001;  116 (1) 63-68
    PubMedGoogle Scholar
  • 82 Brunmair B, Staniek K, Dörig J et al.. Activation of PPAR-delta in isolated rat skeletal muscle switches fuel preference from glucose to fatty acids.  Diabetologia. 2006;  49 (11) 2713-2722
    CrossrefPubMedGoogle Scholar
  • 83 Young M E, Patil S, Ying J et al.. Uncoupling protein 3 transcription is regulated by peroxisome proliferator-activated receptor (alpha) in the adult rodent heart.  FASEB J. 2001;  15 (3) 833-845
    CrossrefPubMedGoogle Scholar
  • 84 Vettor R, Lombardi A M, Fabris R et al.. Lactate infusion in anesthetized rats produces insulin resistance in heart and skeletal muscles.  Metabolism. 1997;  46 (6) 684-690
    CrossrefPubMedGoogle Scholar
  • 85 Sugden M C, Caton P W, Holness M J. PPAR control: it's SIRTainly as easy as PGC.  J Endocrinol. 2010;  204 (2) 93-104
    CrossrefPubMedGoogle Scholar
  • 86 de Lange P, Moreno M, Silvestri E, Lombardi A, Goglia F, Lanni A. Fuel economy in food-deprived skeletal muscle: signaling pathways and regulatory mechanisms.  FASEB J. 2007;  21 (13) 3431-3441
    CrossrefPubMedGoogle Scholar
  • 87 Gerhart-Hines Z, Rodgers J T, Bare O et al.. Metabolic control of muscle mitochondrial function and fatty acid oxidation through SIRT1/PGC-1alpha.  EMBO J. 2007;  26 (7) 1913-1923
    CrossrefPubMedGoogle Scholar
  • 88 Rodgers J T, Lerin C, Haas W, Gygi S P, Spiegelman B M, Puigserver P. Nutrient control of glucose homeostasis through a complex of PGC-1alpha and SIRT1.  Nature. 2005;  434 (7029) 113-118
    CrossrefPubMedGoogle Scholar
  • 89 Baur J A, Pearson K J, Price N L et al.. Resveratrol improves health and survival of mice on a high-calorie diet.  Nature. 2006;  444 (7117) 337-342
    CrossrefPubMedGoogle Scholar
  • 90 Wu X, Chang M S, Mitsialis S A, Kourembanas S. Hypoxia regulates bone morphogenetic protein signaling through C-terminal-binding protein 1.  Circ Res. 2006;  99 (3) 240-247
    CrossrefPubMedGoogle Scholar
  • 91 Zhang Q, Wang S Y, Nottke A C, Rocheleau J V, Piston D W, Goodman R H. Redox sensor CtBP mediates hypoxia-induced tumor cell migration.  Proc Natl Acad Sci U S A. 2006;  103 (24) 9029-9033
    CrossrefPubMedGoogle Scholar
  • 92 Zhang Q, Wang S Y, Fleuriel C et al.. Metabolic regulation of SIRT1 transcription via a HIC1:CtBP corepressor complex.  Proc Natl Acad Sci U S A. 2007;  104 (3) 829-833
    CrossrefPubMedGoogle Scholar
  • 93 Ido Y. Pyridine nucleotide redox abnormalities in diabetes.  Antioxid Redox Signal. 2007;  9 (7) 931-942
    CrossrefPubMedGoogle Scholar
  • 94 Regnault T R, Zhao L, Chiu J S, Gottheil S K, Foran A, Yee S. Peroxisome Proliferator-activated receptor -β/δ, -γ agonists and resveratrol modulate hypoxia induced changes in nuclear receptor activators of muscle oxidative metabolism.  PPAR Res. 2010;  2010 129173
    PubMedGoogle Scholar
  • 95 Lane R H, Chandorkar A K, Flozak A S, Simmons R A. Intrauterine growth retardation alters mitochondrial gene expression and function in fetal and juvenile rat skeletal muscle.  Pediatr Res. 1998;  43 (5) 563-570
    CrossrefPubMedGoogle Scholar
  • 96 Brøns C, Jensen C B, Storgaard H et al.. Mitochondrial function in skeletal muscle is normal and unrelated to insulin action in young men born with low birth weight.  J Clin Endocrinol Metab. 2008;  93 (10) 3885-3892
    CrossrefPubMedGoogle Scholar
  • 97 Szendroedi J, Schmid A I, Chmelik M et al.. Muscle mitochondrial ATP synthesis and glucose transport/phosphorylation in type 2 diabetes.  PLoS Med. 2007;  4 (5) e154
    CrossrefPubMedGoogle Scholar
  • 98 Kliewer S A, Xu H E, Lambert M H, Willson T M. Peroxisome proliferator-activated receptors: from genes to physiology.  Recent Prog Horm Res. 2001;  56 239-263
    CrossrefPubMedGoogle Scholar
  • 99 Macdonald N, Holden P R, Roberts R A. Addition of peroxisome proliferator-activated receptor alpha to guinea pig hepatocytes confers increased responsiveness to peroxisome proliferators.  Cancer Res. 1999;  59 (19) 4776-4780
    PubMedGoogle Scholar
  • 100 Bonen A, Holloway G P, Tandon N N et al.. Cardiac and skeletal muscle fatty acid transport and transporters and triacylglycerol and fatty acid oxidation in lean and Zucker diabetic fatty rats.  Am J Physiol Regul Integr Comp Physiol. 2009;  297 (4) R1202-R1212
    CrossrefPubMedGoogle Scholar
  • 101 Holloway G P, Benton C R, Mullen K L et al.. In obese rat muscle transport of palmitate is increased and is channeled to triacylglycerol storage despite an increase in mitochondrial palmitate oxidation.  Am J Physiol Endocrinol Metab. 2009;  296 (4) E738-E747
    CrossrefPubMedGoogle Scholar
  • 102 Holst D, Luquet S, Nogueira V, Kristiansen K, Leverve X, Grimaldi P A. Nutritional regulation and role of peroxisome proliferator-activated receptor delta in fatty acid catabolism in skeletal muscle.  Biochim Biophys Acta. 2003;  1633 (1) 43-50
    CrossrefPubMedGoogle Scholar
  • 103 Chevillotte E, Rieusset J, Roques M, Desage M, Vidal H. The regulation of uncoupling protein-2 gene expression by omega-6 polyunsaturated fatty acids in human skeletal muscle cells involves multiple pathways, including the nuclear receptor peroxisome proliferator-activated receptor beta.  J Biol Chem. 2001;  276 (14) 10853-10860
    CrossrefPubMedGoogle Scholar
  • 104 Bezaire V, Spriet L L, Campbell S et al.. Constitutive UCP3 overexpression at physiological levels increases mouse skeletal muscle capacity for fatty acid transport and oxidation.  FASEB J. 2005;  19 (8) 977-979
    PubMedGoogle Scholar
  • 105 Brand M D, Pamplona R, Portero-Otín M et al.. Oxidative damage and phospholipid fatty acyl composition in skeletal muscle mitochondria from mice underexpressing or overexpressing uncoupling protein 3.  Biochem J. 2002;  368 (Pt 2) 597-603
    CrossrefPubMedGoogle Scholar
  • 106 Brandt J M, Djouadi F, Kelly D P. Fatty acids activate transcription of the muscle carnitine palmitoyltransferase I gene in cardiac myocytes via the peroxisome proliferator-activated receptor alpha.  J Biol Chem. 1998;  273 (37) 23786-23792
    CrossrefPubMedGoogle Scholar
  • 107 Hulver M W, Dohm G L. The molecular mechanism linking muscle fat accumulation to insulin resistance.  Proc Nutr Soc. 2004;  63 (2) 375-380
    CrossrefPubMedGoogle Scholar
  • 108 Luquet S, Lopez-Soriano J, Holst D et al.. Peroxisome proliferator-activated receptor delta controls muscle development and oxidative capability.  FASEB J. 2003;  17 (15) 2299-2301
    PubMedGoogle Scholar
  • 109 Barak Y, Liao D, He W et al.. Effects of peroxisome proliferator-activated receptor delta on placentation, adiposity, and colorectal cancer.  Proc Natl Acad Sci U S A. 2002;  99 (1) 303-308
    CrossrefPubMedGoogle Scholar
  • 110 Wang Y X, Lee C H, Tiep S et al.. Peroxisome-proliferator-activated receptor delta activates fat metabolism to prevent obesity.  Cell. 2003;  113 (2) 159-170
    CrossrefPubMedGoogle Scholar
  • 111 Wang Y X, Zhang C L, Yu R T et al.. Regulation of muscle fiber type and running endurance by PPARdelta.  PLoS Biol. 2004;  2 (10) e294
    CrossrefPubMedGoogle Scholar
  • 112 Magee T R, Han G, Cherian B, Khorram O, Ross M G, Desai M. Down-regulation of transcription factor peroxisome proliferator-activated receptor in programmed hepatic lipid dysregulation and inflammation in intrauterine growth-restricted offspring.  Am J Obstet Gynecol. 2008;  199 (3) 271-275, e1–e5
    PubMedGoogle Scholar
  • 113 Burdge G C, Slater-Jefferies J, Torrens C, Phillips E S, Hanson M A, Lillycrop K A. Dietary protein restriction of pregnant rats in the F0 generation induces altered methylation of hepatic gene promoters in the adult male offspring in the F1 and F2 generations.  Br J Nutr. 2007;  97 (3) 435-439
    CrossrefPubMedGoogle Scholar
  • 114 Kind K L, Simonetta G, Clifton P M, Robinson J S, Owens J A. Effect of maternal feed restriction on blood pressure in the adult guinea pig.  Exp Physiol. 2002;  87 (4) 469-477
    PubMedGoogle Scholar
  • 115 Kind K L, Clifton P M, Grant P A et al.. Effect of maternal feed restriction during pregnancy on glucose tolerance in the adult guinea pig.  Am J Physiol Regul Integr Comp Physiol. 2003;  284 (1) R140-R152
    PubMedGoogle Scholar
  • 116 Lillycrop K A, Phillips E S, Jackson A A, Hanson M A, Burdge G C. Dietary protein restriction of pregnant rats induces and folic acid supplementation prevents epigenetic modification of hepatic gene expression in the offspring.  J Nutr. 2005;  135 (6) 1382-1386
    PubMedGoogle Scholar
  • 117 Boney C M, Verma A, Tucker R, Vohr B R. Metabolic syndrome in childhood: association with birth weight, maternal obesity, and gestational diabetes mellitus.  Pediatrics. 2005;  115 (3) e290-e296
    CrossrefPubMedGoogle Scholar
  • 118 Gluckman P D, Hanson M A. Metabolic disease: evolutionary, developmental and transgenerational influences. In: Hornstra G, Uauy R, Yang X, eds. The Impact of Maternal Nutrition on the Offspring. Basel, Switzerland: Vevey/S. Karger; 2005: 17-27
    CrossrefGoogle Scholar
  • 119 Simmons R. Developmental origins of adult metabolic disease: concepts and controversies.  Trends Endocrinol Metab. 2005;  16 (8) 390-394
    CrossrefPubMedGoogle Scholar
  • 120 Barker D J, Hales C N, Fall C H, Osmond C, Phipps K, Clark P M. Type 2 (non-insulin-dependent) diabetes mellitus, hypertension and hyperlipidaemia (syndrome X): relation to reduced fetal growth.  Diabetologia. 1993;  36 (1) 62-67
    CrossrefPubMedGoogle Scholar
  • 121 Barker D J. Fetal programming of coronary heart disease.  Trends Endocrinol Metab. 2002;  13 (9) 364-368
    CrossrefPubMedGoogle Scholar
  • 122 Bertram C E, Hanson M A. Animal models and programming of the metabolic syndrome.  Br Med Bull. 2001;  60 103-121
    CrossrefPubMedGoogle Scholar
  • 123 De Blasio M J, Gatford K L, McMillen I C, Robinson J S, Owens J A. Placental restriction of fetal growth increases insulin action, growth, and adiposity in the young lamb.  Endocrinology. 2007;  148 (3) 1350-1358
    PubMedGoogle Scholar
  • 124 Jaquet D, Vidal H, Hankard R, Czernichow P, Levy-Marchal C. Impaired regulation of glucose transporter 4 gene expression in insulin resistance associated with in utero undernutrition.  J Clin Endocrinol Metab. 2001;  86 (7) 3266-3271
    CrossrefPubMedGoogle Scholar
  • 125 Ozanne S E, Olsen G S, Hansen L L et al.. Early growth restriction leads to down regulation of protein kinase C zeta and insulin resistance in skeletal muscle.  J Endocrinol. 2003;  177 (2) 235-241
    CrossrefPubMedGoogle Scholar
  • 126 Sparks L M, Xie H, Koza R A et al.. A high-fat diet coordinately downregulates genes required for mitochondrial oxidative phosphorylation in skeletal muscle.  Diabetes. 2005;  54 (7) 1926-1933
    CrossrefPubMedGoogle Scholar
  • 127 Coll T, Jové M, Rodríguez-Calvo R et al.. Palmitate-mediated downregulation of peroxisome proliferator-activated receptor-gamma coactivator 1alpha in skeletal muscle cells involves MEK1/2 and nuclear factor-kappaB activation.  Diabetes. 2006;  55 (10) 2779-2787
    CrossrefPubMedGoogle Scholar
  • 128 Hoeks J, Hesselink M K, Russell A P et al.. Peroxisome proliferator-activated receptor-gamma coactivator-1 and insulin resistance: acute effect of fatty acids.  Diabetologia. 2006;  49 (10) 2419-2426
    CrossrefPubMedGoogle Scholar
  • 129 Staiger H, Staiger K, Haas C, Weisser M, Machicao F, Häring H U. Fatty acid-induced differential regulation of the genes encoding peroxisome proliferator-activated receptor-gamma coactivator-1alpha and -1beta in human skeletal muscle cells that have been differentiated in vitro.  Diabetologia. 2005;  48 (10) 2115-2118
    CrossrefPubMedGoogle Scholar
  • 130 Bayol S A, Simbi B H, Stickland N C. A maternal cafeteria diet during gestation and lactation promotes adiposity and impairs skeletal muscle development and metabolism in rat offspring at weaning.  J Physiol. 2005;  567 (Pt 3) 951-961
    CrossrefPubMedGoogle Scholar
  • 131 Schaiff W T, Knapp Jr F F, Barak Y, Biron-Shental T, Nelson D M, Sadovsky Y. Ligand-activated peroxisome proliferator activated receptor gamma alters placental morphology and placental fatty acid uptake in mice.  Endocrinology. 2007;  148 (8) 3625-3634
    CrossrefPubMedGoogle Scholar
  • 132 Schaiff W T, Bildirici I, Cheong M, Chern P L, Nelson D M, Sadovsky Y. Peroxisome proliferator-activated receptor-gamma and retinoid X receptor signaling regulate fatty acid uptake by primary human placental trophoblasts.  J Clin Endocrinol Metab. 2005;  90 (7) 4267-4275
    CrossrefPubMedGoogle Scholar
  • 133 Garg M, Thamotharan M, Oak S A et al.. Early exercise regimen improves insulin sensitivity in the intrauterine growth-restricted adult female rat offspring.  Am J Physiol Endocrinol Metab. 2009;  296 (2) E272-E281
    PubMedGoogle Scholar
  • 134 Eriksson J G, Ylihärsilä H, Forsén T, Osmond C, Barker D J. Exercise protects against glucose intolerance in individuals with a small body size at birth.  Prev Med. 2004;  39 (1) 164-167
    CrossrefPubMedGoogle Scholar
  • 135 Koves T R, Ussher J R, Noland R C et al.. Mitochondrial overload and incomplete fatty acid oxidation contribute to skeletal muscle insulin resistance.  Cell Metab. 2008;  7 (1) 45-56
    CrossrefPubMedGoogle Scholar
  • 136 Kim J Y, Hickner R C, Cortright R L, Dohm G L, Houmard J A. Lipid oxidation is reduced in obese human skeletal muscle.  Am J Physiol Endocrinol Metab. 2000;  279 (5) E1039-E1044
    PubMedGoogle Scholar
  • 137 Simoneau J A, Veerkamp J H, Turcotte L P, Kelley D E. Markers of capacity to utilize fatty acids in human skeletal muscle: relation to insulin resistance and obesity and effects of weight loss.  FASEB J. 1999;  13 (14) 2051-2060
    CrossrefPubMedGoogle Scholar
  • 138 Godfrey K M, Lillycrop K A, Burdge G C, Gluckman P D, Hanson M A. Epigenetic mechanisms and the mismatch concept of the developmental origins of health and disease.  Pediatr Res. 2007;  61 (5 Pt 2) 5R-10R
    CrossrefPubMedGoogle Scholar
  • 139 Evans R M, Barish G D, Wang Y X. PPARs and the complex journey to obesity.  Nat Med. 2004;  10 (4) 355-361
    CrossrefPubMedGoogle Scholar
  • 140 Kumar N, Dey C S. Development of insulin resistance and reversal by thiazolidinediones in C2C12 skeletal muscle cells.  Biochem Pharmacol. 2003;  65 (2) 249-257
    CrossrefPubMedGoogle Scholar
  • 141 Kim J E, Chen J. regulation of peroxisome proliferator-activated receptor-gamma activity by mammalian target of rapamycin and amino acids in adipogenesis.  Diabetes. 2004;  53 (11) 2748-2756
    CrossrefPubMedGoogle Scholar
  • 142 Benton C R, Holloway G P, Campbell S E et al.. Rosiglitazone increases fatty acid oxidation and fatty acid translocase (FAT/CD36) but not carnitine palmitoyltransferase I in rat muscle mitochondria.  J Physiol. 2008;  586 (6) 1755-1766
    CrossrefPubMedGoogle Scholar
  • 143 Luquet S, Lopez-Soriano J, Holst D et al.. Roles of peroxisome proliferator-activated receptor delta (PPARdelta) in the control of fatty acid catabolism. A new target for the treatment of metabolic syndrome.  Biochimie. 2004;  86 (11) 833-837
    CrossrefPubMedGoogle Scholar
  • 144 Luquet S, Lopez-Soriano J, Holst D et al.. Roles of peroxisome proliferator-activated receptor delta (PPARdelta) in the control of fatty acid catabolism. A new target for the treatment of metabolic syndrome.  Biochimie. 2004;  86 (11) 833-837
    CrossrefPubMedGoogle Scholar
  • 145 Fiévet C, Fruchart J C, Staels B. PPARalpha and PPARgamma dual agonists for the treatment of type 2 diabetes and the metabolic syndrome.  Curr Opin Pharmacol. 2006;  6 (6) 606-614
    CrossrefPubMedGoogle Scholar
  • 146 Grimaldi P A. Regulatory role of peroxisome proliferator-activated receptor delta (PPAR delta) in muscle metabolism. A new target for metabolic syndrome treatment?.  Biochimie. 2005;  87 (1) 5-8
    CrossrefPubMedGoogle Scholar
  • 147 Takahashi S, Tanaka T, Kodama T, Sakai J. Peroxisome proliferator-activated receptor delta (PPARdelta), a novel target site for drug discovery in metabolic syndrome.  Pharmacol Res. 2006;  53 (6) 501-507
    CrossrefPubMedGoogle Scholar
  • 148 Sprecher D L, Massien C, Pearce G et al.. Triglyceride:high-density lipoprotein cholesterol effects in healthy subjects administered a peroxisome proliferator activated receptor delta agonist.  Arterioscler Thromb Vasc Biol. 2007;  27 (2) 359-365
    PubMedGoogle Scholar
  • 149 Howitz K T, Bitterman K J, Cohen H Y et al.. Small molecule activators of sirtuins extend Saccharomyces cerevisiae lifespan.  Nature. 2003;  425 (6954) 191-196
    CrossrefPubMedGoogle Scholar
  • 150 Sakkinen P A, Wahl P, Cushman M, Lewis M R, Tracy R P. Clustering of procoagulation, inflammation, and fibrinolysis variables with metabolic factors in insulin resistance syndrome.  Am J Epidemiol. 2000;  152 (10) 897-907
    CrossrefPubMedGoogle Scholar
  • 151 Law C M, Shiell A W. Is blood pressure inversely related to birth weight? The strength of evidence from a systematic review of the literature.  J Hypertens. 1996;  14 (8) 935-941
    PubMedGoogle Scholar
  • 152 Curhan G C, Willett W C, Rimm E B, Spiegelman D, Ascherio A L, Stampfer M J. Birth weight and adult hypertension, diabetes mellitus, and obesity in US men.  Circulation. 1996;  94 (12) 3246-3250
    CrossrefPubMedGoogle Scholar
  • 153 Nilsson P M, Ostergren P O, Nyberg P, Söderström M, Allebeck P. Low birth weight is associated with elevated systolic blood pressure in adolescence: a prospective study of a birth cohort of 149378 Swedish boys.  J Hypertens. 1997;  15 (12 Pt 2) 1627-1631
    CrossrefPubMedGoogle Scholar
  • 154 Huxley R R, Shiell A W, Law C M. The role of size at birth and postnatal catch-up growth in determining systolic blood pressure: a systematic review of the literature.  J Hypertens. 2000;  18 (7) 815-831
    CrossrefPubMedGoogle Scholar
  • 155 Grigore D, Ojeda N B, Robertson E B et al.. Placental insufficiency results in temporal alterations in the renin angiotensin system in male hypertensive growth restricted offspring.  Am J Physiol Regul Integr Comp Physiol. 2007;  293 (2) R804-R811
    CrossrefPubMedGoogle Scholar
  • 156 Alexander B T. Placental insufficiency leads to development of hypertension in growth-restricted offspring.  Hypertension. 2003;  41 (3) 457-462
    CrossrefPubMedGoogle Scholar
  • 157 Wlodek M E, Westcott K, Siebel A L, Owens J A, Moritz K M. Growth restriction before or after birth reduces nephron number and increases blood pressure in male rats.  Kidney Int. 2008;  74 (2) 187-195
    CrossrefPubMedGoogle Scholar
  • 158 Verma S, Anderson T J. Fundamentals of endothelial function for the clinical cardiologist.  Circulation. 2002;  105 (5) 546-549
    CrossrefPubMedGoogle Scholar
  • 159 Celermajer D S, Sorensen K E, Bull C, Robinson J, Deanfield J E. Endothelium-dependent dilation in the systemic arteries of asymptomatic subjects relates to coronary risk factors and their interaction.  J Am Coll Cardiol. 1994;  24 (6) 1468-1474
    CrossrefPubMedGoogle Scholar
  • 160 Dimmeler S, Fleming I, Fisslthaler B, Hermann C, Busse R, Zeiher A M. Activation of nitric oxide synthase in endothelial cells by Akt-dependent phosphorylation.  Nature. 1999;  399 (6736) 601-605
    CrossrefPubMedGoogle Scholar
  • 161 Montagnani M, Golovchenko I, Kim I et al.. Inhibition of phosphatidylinositol 3-kinase enhances mitogenic actions of insulin in endothelial cells.  J Biol Chem. 2002;  277 (3) 1794-1799
    CrossrefPubMedGoogle Scholar
  • 162 Musicki B, Liu T, Lagoda G A et al.. Hypercholesterolemia-induced erectile dysfunction: endothelial nitric oxide synthase (eNOS) uncoupling in the mouse penis by NAD(P)H oxidase.  J Sex Med. 2010;  7 (9) 3023-3032
    CrossrefPubMedGoogle Scholar
  • 163 Li H, Li H, Bao Y, Zhang X, Yu Y. Free fatty acids induce endothelial dysfunction and activate protein kinase C and nuclear factor-kappaB pathway in rat aorta.  Int J Cardiol. 2010;  August 5 (Epub ahead of print)
    PubMedGoogle Scholar
  • 164 Goodfellow J, Bellamy M F, Gorman S T et al.. Endothelial function is impaired in fit young adults of low birth weight.  Cardiovasc Res. 1998;  40 (3) 600-606
    CrossrefPubMedGoogle Scholar
  • 165 Leeson C P, Kattenhorn M, Morley R, Lucas A, Deanfield J E. Impact of low birth weight and cardiovascular risk factors on endothelial function in early adult life.  Circulation. 2001;  103 (9) 1264-1268
    CrossrefPubMedGoogle Scholar
  • 166 Martin H, Hu J, Gennser G, Norman M. Impaired endothelial function and increased carotid stiffness in 9-year-old children with low birthweight.  Circulation. 2000;  102 (22) 2739-2744
    CrossrefPubMedGoogle Scholar
  • 167 Leeson C P, Whincup P H, Cook D G et al.. Flow-mediated dilation in 9- to 11-year-old children: the influence of intrauterine and childhood factors.  Circulation. 1997;  96 (7) 2233-2238
    CrossrefPubMedGoogle Scholar
  • 168 Payne J A, Alexander B T, Khalil R A. Reduced endothelial vascular relaxation in growth-restricted offspring of pregnant rats with reduced uterine perfusion.  Hypertension. 2003;  42 (4) 768-774
    CrossrefPubMedGoogle Scholar
  • 169 Berliner J A, Heinecke J W. The role of oxidized lipoproteins in atherogenesis.  Free Radic Biol Med. 1996;  20 (5) 707-727
    CrossrefPubMedGoogle Scholar
  • 170 Huang K, Zou C C, Yang X Z, Chen X Q, Liang L. Carotid intima-media thickness and serum endothelial marker levels in obese children with metabolic syndrome.  Arch Pediatr Adolesc Med. 2010;  164 (9) 846-851
    CrossrefPubMedGoogle Scholar
  • 171 Redon J, Cifkova R, Laurent S et al.. Mechanisms of hypertension in the cardiometabolic syndrome.  J Hypertens. 2009;  27 (3) 441-451
    CrossrefPubMedGoogle Scholar
  • 172 Oren A, Vos L E, Uiterwaal C S, Gorissen W H, Grobbee D E, Bots M L. Birth weight and carotid intima-media thickness: new perspectives from the atherosclerosis risk in young adults (ARYA) study.  Ann Epidemiol. 2004;  14 (1) 8-16
    CrossrefPubMedGoogle Scholar
  • 173 Koklu E, Kurtoglu S, Akcakus M et al.. Increased aortic intima-media thickness is related to lipid profile in newborns with intrauterine growth restriction.  Horm Res. 2006;  65 (6) 269-275
    CrossrefPubMedGoogle Scholar
  • 174 Koklu E, Ozturk M A, Kurtoglu S, Akcakus M, Yikilmaz A, Gunes T. Aortic intima-media thickness, serum IGF-I, IGFBP-3, and leptin levels in intrauterine growth-restricted newborns of healthy mothers.  Pediatr Res. 2007;  62 (6) 704-709
    CrossrefPubMedGoogle Scholar
  • 175 Morgan D A, Rahmouni K. Differential effects of insulin on sympathetic nerve activity in agouti obese mice.  J Hypertens. 2010;  28 (9) 1913-1919
    CrossrefPubMedGoogle Scholar
  • 176 Lambert G W, Straznicky N E, Lambert E A, Dixon J B, Schlaich M P. Sympathetic nervous activation in obesity and the metabolic syndrome—causes, consequences and therapeutic implications.  Pharmacol Ther. 2010;  126 (2) 159-172
    CrossrefPubMedGoogle Scholar
  • 177 Jansson T, Lambert G W. Effect of intrauterine growth restriction on blood pressure, glucose tolerance and sympathetic nervous system activity in the rat at 3-4 months of age.  J Hypertens. 1999;  17 (9) 1239-1248
    CrossrefPubMedGoogle Scholar
  • 178 Ojeda N B, Royals T P, Black J T, Dasinger J H, Johnson J M, Alexander B T. Enhanced sensitivity to acute angiotensin II is testosterone dependent in adult male growth-restricted offspring.  Am J Physiol Regul Integr Comp Physiol. 2010;  298 (5) R1421-R1427
    CrossrefPubMedGoogle Scholar
  • 179 Grigore D, Ojeda N B, Robertson E B et al.. Placental insufficiency results in temporal alterations in the renin angiotensin system in male hypertensive growth restricted offspring.  Am J Physiol Regul Integr Comp Physiol. 2007;  293 (2) R804-R811
    CrossrefPubMedGoogle Scholar
  • 180 Konje J C, Okaro C I, Bell S C, de Chazal R, Taylor D J. A cross-sectional study of changes in fetal renal size with gestation in appropriate- and small-for-gestational-age fetuses.  Ultrasound Obstet Gynecol. 1997;  10 (1) 22-26
    CrossrefPubMedGoogle Scholar
  • 181 Spencer J, Wang Z, Hoy W. Low birth weight and reduced renal volume in Aboriginal children.  Am J Kidney Dis. 2001;  37 (5) 915-920
    CrossrefPubMedGoogle Scholar
  • 182 Hinchliffe S A, Lynch M R, Sargent P H, Howard C V, Van Velzen D. The effect of intrauterine growth retardation on the development of renal nephrons.  Br J Obstet Gynaecol. 1992;  99 (4) 296-301
    CrossrefPubMedGoogle Scholar
  • 183 Moritz K M, Mazzuca M Q, Siebel A L et al.. Uteroplacental insufficiency causes a nephron deficit, modest renal insufficiency but no hypertension with ageing in female rats.  J Physiol. 2009;  587 (Pt 11) 2635-2646
    CrossrefPubMedGoogle Scholar
  • 184 Martin J A, Osterman M J, Sutton P D. Are preterm births on the decline in the United States? Recent data from the National Vital Statistics System.  NCHS Data Brief. 2010;  39 1-8
    PubMedGoogle Scholar
  • 185 Martin J A, Hamilton B E, Sutton P D Centers for Disease Control and Prevention National Center for Health Statistics National Vital Statistics System et al. Births: final data for 2005.  Natl Vital Stat Rep. 2007;  56 (6) 1-103
    PubMedGoogle Scholar

Timothy R.H. RegnaultPh.D. 

Department of Obstetrics and Gynaecology

The University of Western Ontario, London, ON, Canada N6A 5C1

Email: tim.regnault@uwo.ca

      >